67 related articles for article (PubMed ID: 11034070)
1. Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.
Tillman H; Vogel P; Rogers T; Akers W; Rehg JE
Vet Pathol; 2020 May; 57(3):445-456. PubMed ID: 32202225
[TBL] [Abstract][Full Text] [Related]
2. BCR signaling is required for posttransplant lymphoproliferative disease in immunodeficient mice receiving human B cells.
Zhang TT; Cheng RY; Ott AR; Dahl NP; Suchland ER; Stoffers CM; Asher GD; Hou D; Thouvenel CD; Hill TF; Rawlings DJ; James RG
Sci Transl Med; 2024 Apr; 16(742):eadh8846. PubMed ID: 38598616
[TBL] [Abstract][Full Text] [Related]
3. Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines.
Houldcroft CJ; Petrova V; Liu JZ; Frampton D; Anderson CA; Gall A; Kellam P
PLoS One; 2014; 9(10):e108384. PubMed ID: 25290448
[TBL] [Abstract][Full Text] [Related]
4. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
[TBL] [Abstract][Full Text] [Related]
5. Membrane-bound CD95 ligand modulates CD19-mediated B cell receptor signaling and EBV activation.
Liu M; Huang C; Zhou X; Jiang C; Liu S; Gao Y; Kuang L; Lei Z; Jia R; Xu J; Legembre P; Liang X
J Med Virol; 2024 Feb; 96(2):e29440. PubMed ID: 38299675
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of IRE1alpha/XBP1 axis prevents EBV-driven lymphomagenesis in NSG mice.
Arena A; Romeo MA; Po A; Benedetti R; Gilardini Montani MS; Gonnella R; Santarelli R; Gaeta A; De Smaele E; Cirone M
Microbiol Spectr; 2023 Dec; 11(6):e0263623. PubMed ID: 37882554
[TBL] [Abstract][Full Text] [Related]
7. A Novel Homozygous Six Base Pair Deletion Found in the NFATC2 Gene in a Patient with EBV-Associated Lymphoproliferation.
Erman B; Bal SK; Aydoğmuş Ç; Ersoy GZ; Boztug K
J Clin Immunol; 2024 Mar; 44(3):74. PubMed ID: 38427060
[No Abstract] [Full Text] [Related]
8. The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
Robert A; Pujals A; Favre L; Debernardi J; Wiels J
Mol Oncol; 2020 Oct; 14(10):2520-2532. PubMed ID: 32623836
[TBL] [Abstract][Full Text] [Related]
9. Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.
Ludwig LM; Nassin ML; Hadji A; LaBelle JL
Front Pediatr; 2016; 4():135. PubMed ID: 28066751
[TBL] [Abstract][Full Text] [Related]
10. Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer.
Alibek K; Irving S; Sautbayeva Z; Kakpenova A; Bekmurzayeva A; Baiken Y; Imangali N; Shaimerdenova M; Mektepbayeva D; Balabiyev A; Chinybayeva A
Infect Agent Cancer; 2014; 9():44. PubMed ID: 25699089
[TBL] [Abstract][Full Text] [Related]
11. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
12. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient.
Yin CC; Medeiros LJ; Abruzzo LV; Jones D; Farhood AI; Thomazy VA
Am J Clin Pathol; 2005 Feb; 123(2):222-8. PubMed ID: 15842046
[TBL] [Abstract][Full Text] [Related]
13. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases.
Cohen JI
Semin Hematol; 2003 Apr; 40(2):116-23. PubMed ID: 12704588
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
16. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
